Deirdre K Tobias1, Samia Mora1,2, Subodh Verma3, Patrick R Lawler4. 1. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital Harvard Medical School. 2. Center for Lipid Metabolomics and Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3. Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto. 4. Peter Munk Cardiac Centre, University Health Network, and Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: Atherosclerotic cardiovascular disease (CVD) and type II diabetes (T2D) share common etiologic pathways that may long precede the development of clinically evident disease. Early identification of risk markers could support efforts to individualize risk prediction and improve the efficacy of primary prevention, as well as uncover novel therapeutic targets. RECENT FINDINGS: Altered metabolism of branched-chain amino acids (BCAAs), and their subsequent accumulation in circulation, may precede the development of insulin resistance and clinically manifest cardiometabolic diseases. BCAAs - the essential amino acids leucine, isoleucine and valine - likely promote insulin resistance through activation of mammalian target of rapamycin complex 1. Epidemiologic studies demonstrate robust associations between BCAAs and incident T2D, and Mendelian randomization supports a potentially causal relationship. More recently, there is emerging evidence that BCAAs are also associated with incident atherosclerotic CVD, possibly mediated by the development of T2D. SUMMARY: In this article, we review the biochemistry of BCAAs, their potential contribution to cardiometabolic risk, the available evidence from molecular epidemiologic studies to date, and, finally, consider future research and clinical directions. Overall, BCAAs represent a promising emerging target for risk stratification and possible intervention, to support efforts to mitigate the burden of cardiometabolic disease in the population.
PURPOSE OF REVIEW: Atherosclerotic cardiovascular disease (CVD) and type II diabetes (T2D) share common etiologic pathways that may long precede the development of clinically evident disease. Early identification of risk markers could support efforts to individualize risk prediction and improve the efficacy of primary prevention, as well as uncover novel therapeutic targets. RECENT FINDINGS: Altered metabolism of branched-chain amino acids (BCAAs), and their subsequent accumulation in circulation, may precede the development of insulin resistance and clinically manifest cardiometabolic diseases. BCAAs - the essential amino acids leucine, isoleucine and valine - likely promote insulin resistance through activation of mammalian target of rapamycin complex 1. Epidemiologic studies demonstrate robust associations between BCAAs and incident T2D, and Mendelian randomization supports a potentially causal relationship. More recently, there is emerging evidence that BCAAs are also associated with incident atherosclerotic CVD, possibly mediated by the development of T2D. SUMMARY: In this article, we review the biochemistry of BCAAs, their potential contribution to cardiometabolic risk, the available evidence from molecular epidemiologic studies to date, and, finally, consider future research and clinical directions. Overall, BCAAs represent a promising emerging target for risk stratification and possible intervention, to support efforts to mitigate the burden of cardiometabolic disease in the population.
Authors: Yan Zheng; Yanping Li; Qibin Qi; Adela Hruby; JoAnn E Manson; Walter C Willett; Brian M Wolpin; Frank B Hu; Lu Qi Journal: Int J Epidemiol Date: 2016-07-13 Impact factor: 7.196
Authors: Erin L Glynn; Lucy W Piner; Kim M Huffman; Cris A Slentz; Lorraine Elliot-Penry; Hiba AbouAssi; Phillip J White; James R Bain; Michael J Muehlbauer; Olga R Ilkayeva; Robert D Stevens; Kathryn N Porter Starr; Connie W Bales; Elena Volpi; M Julia Brosnan; Jeff K Trimmer; Timothy P Rolph; Christopher B Newgard; William E Kraus Journal: Diabetologia Date: 2015-08-09 Impact factor: 10.122
Authors: Geoffrey A Walford; Yong Ma; Clary Clish; Jose C Florez; Thomas J Wang; Robert E Gerszten Journal: Diabetes Date: 2016-02-09 Impact factor: 9.461
Authors: D Preiss; N Rankin; P Welsh; R R Holman; A J Kangas; P Soininen; P Würtz; M Ala-Korpela; N Sattar Journal: Diabet Med Date: 2016-03-03 Impact factor: 4.359
Authors: Ryoko Katagiri; Mingyang Song; Xuehong Zhang; Dong Hoon Lee; Fred K Tabung; Charles S Fuchs; Jeffrey A Meyerhardt; Reiko Nishihara; Andrew T Chan; Amit D Joshi; Motoki Iwasaki; Shuji Ogino; Walter C Willett; Edward Giovannucci; Kana Wu Journal: Cancer Prev Res (Phila) Date: 2019-11-07
Authors: Kathleen M McClain; Christine M Friedenreich; Charles E Matthews; Joshua N Sampson; David P Check; Darren R Brenner; Kerry S Courneya; Rachel A Murphy; Steven C Moore Journal: J Nutr Date: 2022-02-08 Impact factor: 4.798
Authors: Deirdre K Tobias; Samia Mora; Subodh Verma; Filio Billia; Julie E Buring; Patrick R Lawler Journal: Metabolism Date: 2020-10-15 Impact factor: 13.934
Authors: Rikuta Hamaya; Samia Mora; Patrick R Lawler; Nancy R Cook; Paul M Ridker; Julie E Buring; I-Min Lee; JoAnn E Manson; Deirdre K Tobias Journal: Circ Genom Precis Med Date: 2021-07-15
Authors: Karissa M Dieseldorff Jones; Cynthia Vied; Isela C Valera; P Bryant Chase; Michelle S Parvatiyar; Jose R Pinto Journal: Physiol Rep Date: 2020-03
Authors: Edgar E Nollet; B Daan Westenbrink; Rudolf A de Boer; Diederik W D Kuster; Jolanda van der Velden Journal: J Am Heart Assoc Date: 2020-11-11 Impact factor: 6.106
Authors: Karema Al Rashid; Amy Taylor; Mary Ann Lumsden; Neil Goulding; Deborah A Lawlor; Scott M Nelson Journal: BMC Med Date: 2020-08-31 Impact factor: 8.775